Go Further: Partnership to End AIDS and Cervical Cancer
Active Since: 2019
Contributing to SDGs…
In 2019, our company joined the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute (Bush Institute) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) in the Go Further: Partnership to End AIDS and Cervical Cancer among HIV-positive women in Africa.
US Presidents Emergency Plan for AIDS Relief (PEPFAR)
Intergovernmental Organizations and Multilaterals
Private foundation or development organization
George W. Bush Institute (Bush Institute)
In 2019, MSD* joined PEPFAR, the George W. Bush Institute, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) in the Go Further Partnership, an effort to reduce new cervical cancer cases by 95 percent among the estimated 3.8 million HIV-positive women who live in eight high-burden African countries. Human papillomavirus (HPV) is the major cause of cervical cancer, and women who are HIV-positive are four to five times more likely to develop invasive cervical cancer. Through this partnership, we are addressing cervical cancer in HIV-positive women in Sub-Saharan Africa, not only through screening and treatment, but also through prevention.
*MSD is known as Merck & Co., Inc. in the US & Canada
At Merck, we are committed to addressing the health care needs of women in the developing world and are pleased to support PEPFAR on this important initiative. Through this partnership we will be addressing HPV infection in a population most heavily impacted by HPV related cancer, not only through screening for and treating HPV, but also preventing it in the first place.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.1: Reduce Maternal Mortality
- 3.2: Reduce Under-5 Mortality
- 3.7: Access to sexual and reproductive health-care services
SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
As of March 30, 2020, the Go Further partnership has supported over 1 million cervical cancer screenings for women living with HIV, including 87% for whom it was a first-time screening, and treated over 50,000 women for pre-invasive cancerous lesions.
To address these risks, Go Further is increasing access to the human papillomavirus vaccine (HPV) to prevent cervical cancer, expanding the availability of vital cervical cancer screening, and providing treatment for women most vulnerable to developing cervical cancer. With minimal additional investment, these low-cost interventions can save millions of lives and help secure global gains against HIV/AIDS.